These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1207 related articles for article (PubMed ID: 11038142)

  • 21. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y; Kyprianou N
    Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.
    Tørring N; Jørgensen PE; Sørensen BS; Nexø E
    Anticancer Res; 2000; 20(1A):91-5. PubMed ID: 10769639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
    Serafin AM; Akudugu JM; Bohm L
    Urol Res; 2002 Oct; 30(5):289-94. PubMed ID: 12389116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
    Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
    Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
    Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
    Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells.
    Song Z; Powell WC; Kasahara N; van Bokhoven A; Miller GJ; Roy-Burman P
    Cancer Res; 2000 Dec; 60(23):6730-6. PubMed ID: 11118059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events.
    Sirotnak FM; She Y; Khokhar NZ; Hayes P; Gerald W; Scher HI
    Mol Carcinog; 2004 Nov; 41(3):150-63. PubMed ID: 15390081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
    Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
    Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer.
    Blok LJ; Chang GT; Steenbeek-Slotboom M; van Weerden WM; Swarts HG; De Pont JJ; van Steenbrugge GJ; Brinkmann AO
    Br J Cancer; 1999 Sep; 81(1):28-36. PubMed ID: 10487609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
    Eder IE; Culig Z; Ramoner R; Thurnher M; Putz T; Nessler-Menardi C; Tiefenthaler M; Bartsch G; Klocker H
    Cancer Gene Ther; 2000 Jul; 7(7):997-1007. PubMed ID: 10917202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular alterations associated with LNCaP cell progression to androgen independence.
    Shi XB; Ma AH; Tepper CG; Xia L; Gregg JP; Gandour-Edwards R; Mack PC; Kung HJ; deVere White RW
    Prostate; 2004 Aug; 60(3):257-71. PubMed ID: 15176055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression.
    Xu LL; Shi Y; Petrovics G; Sun C; Makarem M; Zhang W; Sesterhenn IA; McLeod DG; Sun L; Moul JW; Srivastava S
    Cancer Res; 2003 Aug; 63(15):4299-304. PubMed ID: 12907594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF; Wang Y; Cho JY; Libermann TA
    Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen.
    Miyake H; Hara I; Gleave ME; Eto H
    Prostate; 2004 Dec; 61(4):318-23. PubMed ID: 15389725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.